A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Amgen
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Stanford University
Nagoya City University
UNC Lineberger Comprehensive Cancer Center
The Lymphoma Academic Research Organisation
University Health Network, Toronto
Abramson Cancer Center at Penn Medicine
Washington University School of Medicine
Ruijin Hospital
University of Nebraska
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Fudan University
Massachusetts Eye and Ear Infirmary
Amgen
Singapore General Hospital
Peking University People's Hospital
Greenwich LifeSciences, Inc.
Assistance Publique - Hôpitaux de Paris
City of Hope Medical Center
Allogene Therapeutics
Medical College of Wisconsin
Novartis
Dartmouth-Hitchcock Medical Center
Second Xiangya Hospital of Central South University
H. Lee Moffitt Cancer Center and Research Institute
Aarhus University Hospital
MedSIR
University of Oklahoma
Tempus AI
Peking University People's Hospital
PETHEMA Foundation
Peking University People's Hospital
Sun Yat-sen University
Institute of Hematology & Blood Diseases Hospital, China
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Asan Medical Center
Columbia University
University of Chicago
Caris Science, Inc.
Assistance Publique - Hôpitaux de Paris
Tongji Hospital
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Anhui Medical University
Columbia University